Literature DB >> 19955276

Clinical and microbial characteristics of invasive Streptococcus pyogenes disease in New Caledonia, a region in Oceania with a high incidence of acute rheumatic fever.

S Le Hello1, A Doloy, F Baumann, N Roques, P Coudene, B Rouchon, F Lacassin, A Bouvet.   

Abstract

New Caledonia is an archipelago in the South Pacific with a high prevalence of acute rheumatic fever and rheumatic heart disease. Conducted in 2006, this study aimed at characterizing clinical manifestations and microbial features of isolates obtained from invasive Streptococcus pyogenes disease. Clinical and demographic data were collected prospectively. Isolates were biotyped, T typed, emm sequenced, and tested for antibiotic susceptibility. Detection of the speA, speB, speC, and ssa genes was also carried out. The estimated annual incidence of invasive S. pyogenes disease in 2006 was high at 38 cases/100,000 inhabitants in New Caledonia. Invasive isolates were obtained from 90 patients with necrotizing fasciitis (41 cases), bacteremia with no identified focus (12 cases), myositis (10 cases), septic arthritis (9 cases), erysipelas (8 cases), postpartum infection (4 cases), myelitis and osteomyelitis (3 cases), severe pneumonia (2 cases), and endocarditis (1 case). The most frequent associated comorbidities were skin lesions (71%) and obesity (29%). Thirty-one different emm types were identified, and the following six accounted for 54% of the isolates: emm15 (15.5%), emm92 (12.2%), emm106 (8.9%), emm74 (6.7%), emm89 (5.6%), and emm109 (5.6%). The speA, speC, and ssa genes were expressed at different frequencies in the various emm types. The first epidemiological study of invasive S. pyogenes disease in New Caledonia highlights that emm type distribution is particular and should be taken into account in the development of an appropriate vaccine. These findings support the prevention of pyoderma and other cutaneous lesions in order to limit the development of both invasive disease and poststreptococcal sequelae in the South Pacific.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19955276      PMCID: PMC2815587          DOI: 10.1128/JCM.01205-09

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  22 in total

1.  Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis.

Authors:  D R Johnson; D L Stevens; E L Kaplan
Journal:  J Infect Dis       Date:  1992-08       Impact factor: 5.226

2.  Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci.

Authors:  B Beall; R Facklam; T Thompson
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

Review 3.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

4.  Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections.

Authors: 
Journal:  JAMA       Date:  1993-01-20       Impact factor: 56.272

5.  Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat.

Authors:  D E Bessen; J R Carapetis; B Beall; R Katz; M Hibble; B J Currie; T Collingridge; M W Izzo; D A Scaramuzzino; K S Sriprakash
Journal:  J Infect Dis       Date:  2000-09-08       Impact factor: 5.226

6.  Acute rheumatic fever in Auckland, New Zealand: spectrum of associated group A streptococci different from expected.

Authors:  D R Martin; L M Voss; S J Walker; D Lennon
Journal:  Pediatr Infect Dis J       Date:  1994-04       Impact factor: 2.129

7.  Streptococcal emm types in Hawaii: a region with high incidence of acute rheumatic fever.

Authors:  Guliz Erdem; Carla Mizumoto; David Esaki; Lucienne Abe; Venu Reddy; Paul V Effler
Journal:  Pediatr Infect Dis J       Date:  2009-01       Impact factor: 2.129

8.  High burden of invasive beta-haemolytic streptococcal infections in Fiji.

Authors:  A C Steer; A J W Jenney; F Oppedisano; M R Batzloff; J Hartas; J Passmore; F M Russell; J H H Kado; J R Carapetis
Journal:  Epidemiol Infect       Date:  2007-07-16       Impact factor: 2.451

9.  Changing epidemiology of group A streptococcal infection in the USA.

Authors:  B Schwartz; R R Facklam; R F Breiman
Journal:  Lancet       Date:  1990-11-10       Impact factor: 79.321

10.  Clinical and microbiological characteristics of severe Streptococcus pyogenes disease in Europe.

Authors:  Bogdan Luca-Harari; Jessica Darenberg; Shona Neal; Tuula Siljander; Lenka Strakova; Asha Tanna; Roberta Creti; Kim Ekelund; Maria Koliou; Panayotis T Tassios; Mark van der Linden; Monica Straut; Jaana Vuopio-Varkila; Anne Bouvet; Androulla Efstratiou; Claes Schalén; Birgitta Henriques-Normark; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2009-01-21       Impact factor: 5.948

View more
  11 in total

1.  Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Authors:  Manisha Pandey; Michael R Batzloff; Michael F Good
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  Epidemiological and molecular analysis of Streptococcus pyogenes isolates causing invasive disease in Spain (1998-2009): comparison with non-invasive isolates.

Authors:  M Montes; C Ardanuy; E Tamayo; A Domènech; J Liñares; E Pérez-Trallero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-15       Impact factor: 3.267

Review 3.  Current insights in invasive group A streptococcal infections in pediatrics.

Authors:  Anne Filleron; Eric Jeziorski; Anne-Laure Michon; Michel Rodière; Hélène Marchandin
Journal:  Eur J Pediatr       Date:  2012-02-25       Impact factor: 3.183

Review 4.  Molecular insight into invasive group A streptococcal disease.

Authors:  Jason N Cole; Timothy C Barnett; Victor Nizet; Mark J Walker
Journal:  Nat Rev Microbiol       Date:  2011-09-16       Impact factor: 60.633

5.  Clinical and microbiologic characteristics of invasive Streptococcus pyogenes infections in north and south India.

Authors:  Axana Haggar; Andreas Nerlich; Rajesh Kumar; Vinod J Abraham; Kootallur N Brahmadathan; Pallab Ray; Vanita Dhanda; John Melbin Jose Joshua; Narinder Mehra; Rene Bergmann; G Singh Chhatwal; Anna Norrby-Teglund
Journal:  J Clin Microbiol       Date:  2012-02-22       Impact factor: 5.948

6.  Epidemiology and molecular characterization of macrolide-resistant Streptococcus pyogenes in Taiwan.

Authors:  Chia-Ying Huang; Jui-Fen Lai; I-Wen Huang; Pei-Chen Chen; Hui-Ying Wang; Yih-Ru Shiau; Ya-Wen Cheng; Li-Yun Hsieh; Shan-Chwen Chang; Tsai-Ling Yang Lauderdale
Journal:  J Clin Microbiol       Date:  2013-12-04       Impact factor: 5.948

7.  Canada-Wide Epidemic of emm74 Group A Streptococcus Invasive Disease.

Authors:  Sarah Teatero; Allison McGeer; Gregory J Tyrrell; Linda Hoang; Hanan Smadi; Marc-Christian Domingo; Paul N Levett; Michael Finkelstein; Ken Dewar; Agron Plevneshi; Taryn B T Athey; Jonathan B Gubbay; Michael R Mulvey; Irene Martin; Walter Demczuk; Nahuel Fittipaldi
Journal:  Open Forum Infect Dis       Date:  2018-04-20       Impact factor: 3.835

8.  The worldwide epidemiology of acute rheumatic fever and rheumatic heart disease.

Authors:  Michael D Seckeler; Tracey R Hoke
Journal:  Clin Epidemiol       Date:  2011-02-22       Impact factor: 4.790

Review 9.  Invasive group a streptococcal disease: epidemiology, pathogenesis and management.

Authors:  Andrew C Steer; Theresa Lamagni; Nigel Curtis; Jonathan R Carapetis
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

10.  Characterization of streptokinases from group A Streptococci reveals a strong functional relationship that supports the coinheritance of plasminogen-binding M protein and cluster 2b streptokinase.

Authors:  Yueling Zhang; Zhong Liang; Hsing-Tse Hsueh; Victoria A Ploplis; Francis J Castellino
Journal:  J Biol Chem       Date:  2012-10-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.